10X Genomics (TXG)

Executive Summary

10X Genomics is a leading provider of single-cell and spatial genomics solutions, powering over 10,000 publications with its Chromium, Xenium, and Visium platforms. The company is essential infrastructure for modern biological research, with applications in oncology, immunology, and drug development. Despite macroeconomic headwinds impacting biotech funding, 10X maintains a dominant market position and continues to innovate with new product iterations. Recent focus on expanding spatial capabilities and improving throughput positions the company for long-term growth as research spending recovers. The company's public listing (TXG) provides transparency and access to capital markets.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation Xenium in situ platform with enhanced resolution and throughput70% success
• Q3 2026Release of new Chromium single-cell multiome kits enabling simultaneous RNA and protein analysis80% success
• H2 2026Major pharmaceutical partnership for spatial genomics in clinical trials60% success